Type 1 Diabetes Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight's, "Type 1 Diabetes Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Type 1 Diabetes pipeline landscape. It covers the Type 1 Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Type 1 Diabetes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Type 1 Diabetes Pipeline Report

* DelveInsight's Type 1 Diabetes pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Type 1 Diabetes treatment.
* The leading companies working in the Type 1 Diabetes Market include Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, and others.
* Promising Type 1 Diabetes Pipeline Therapies in the various stages of development include Euglycemic clamp with BC Combo THDB0207, ORMD-0801 Treatment A, Dapagliflozin, Mylan's insulin glargine, Lantus Registered , and others.
* May 2024:- Vertex Pharmaceuticals- A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus. The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
* May 2024:- Op-T LLC- A Phase 1b Study of OPT101 in Patients With Type 1 Diabetes. Phase 1b designed to assess safety, pharmacokinetics, immunological and clinical effects of multiple ascending doses of OPT101.

Request a sample and discover the recent advances in Type 1 Diabetes @ Type 1 Diabetes Pipeline Outlook Report [https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Type 1 Diabetes Overview

Type 1 diabetes (also known as diabetes mellitus) is an autoimmune disease in which immune cells attack and destroy the insulin-producing cells of the pancreas. Type 1 diabetes mellitus (T1DM) is an autoimmune disease that leads to the destruction of insulin-producing pancreatic beta cells. Insulin is an essential anabolic hormone that exerts multiple effects on glucose, lipid, protein, and mineral metabolism, as well as growth. Importantly, insulin allows glucose to enter muscle and adipose cells, stimulates the liver to store glucose as glycogen and synthesize fatty acids, stimulates the uptake of amino acids, inhibits the breakdown of fat in adipose tissue, and stimulates the uptake of potassium into cells. Individuals with type 1 diabetes mellitus require life-long insulin replacement therapy. Without insulin, diabetic ketoacidosis (DKA) develops and is life-threatening.

Type 1 Diabetes Emerging Drugs Profile

* Teplizumab: Prevention Bio

Teplizumab is an investigational anti-CD3 monoclonal antibody (mAb) being developed for the delay of clinical type 1 diabetes (T1D) in at-risk individuals. In the pivotal TN-10 Study, a single 14-day course of teplizumab delayed insulin-dependent, clinical-stage disease by a median of at least two years in presymptomatic patients with Stage 2 T1D compared to placebo. The observed adverse events were mechanism-based, transient, and predictable, including lymphopenia, transaminase elevations, rash, and cytokine release events.

* Emricasan: Histogen

Emricasan is a potential first-in-class, orally active, pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Histogen acquired certain rights to emricasan and other caspase inhibitor compounds as a part of its merger with Conatus Pharmaceuticals Inc. in 2020.

* VX-880: Vertex Pharmaceuticals

VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. VX-880 is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. VX-880 has the potential to restore the body's ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. VX-880 is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection.

Learn more about Type 1 Diabetes in clinical trials @ Type 1 Diabetes Drugs [https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Type 1 Diabetes Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies Type 1 Diabetes. The Type 1 Diabetes companies which have their Type 1 Diabetes drug candidates in the most advanced stage, i.e preregistration include Provention Bio

DelveInsight's Type 1 Diabetes pipeline report covers around 100+ products under different phases of clinical development like

* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates

Discover more about Type 1 Diabetes in development @ Type 1 Diabetes Clinical Trials [https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Type 1 Diabetes Companies

Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, and others.

Type 1 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

* Oral
* Intravenous
* Subcutaneous

Type 1 Diabetes Products have been categorized under various Molecule types such as

* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy

To know more about Type 1 Diabetes, visit @ Type 1 Diabetes Segmentation [https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Type 1 Diabetes Pipeline Report

* Coverage- Global
* Type 1 Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Type 1 Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Type 1 Diabetes Companies- Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, and others.
* Type 1 Diabetes Pipeline Therapies- Euglycemic clamp with BC Combo THDB0207, ORMD-0801 Treatment A, Dapagliflozin, Mylan's insulin glargine, Lantus Registered , and others.

For further information on the Type 1 Diabetes Pipeline Therapeutics, reach out @ Type 1 Diabetes Products Development [https://www.delveinsight.com/sample-request/type-1-diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Type 1 Diabetes: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Type 1 Diabetes- DelveInsight's Analytical Perspective
* Late Stage Products (Preregistration)
* Teplizumab: Provention Bio
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* TTP 399: Novo Nordisk
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* SBP 101: Takeda Oncology
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Eflornithine oral: Panbela Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Type 1 Diabetes Key Companies
* Type 1 Diabetes Key Products
* Type 1 Diabetes- Unmet Needs
* Type 1 Diabetes- Market Drivers and Barriers
* Type 1 Diabetes- Future Perspectives and Conclusion
* Type 1 Diabetes Analyst Views
* Type 1 Diabetes Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=type-1-diabetes-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.